NAPLEX Practice Question # 13
NAPLEX Examination:
Take Practice Question for the NAPLEX Exam:
Quiz-summary
0 of 1 questions completed
Questions:
- 1
Information
Naplex
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Results
0 of 1 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 points, (0)
Categories
- Not categorized 0%
- 1
- Answered
- Review
- Question 1 of 1
1. Question
A patient with stage I hypertension who has bronchospastic airway disease and who is noncompliant would be best treated with which of the following -blocking agents?
CorrectAnswer & Explanation:
Th e answer is D
Explanation:
Th e -adrenergic blocking agents continue to demonstrate effectiveness in the treatment of hypertension. A major feature of some of these agents is their relative selectivity for 1-receptors (in the heart) rather than for 2-receptors (in the lung), which provides advantages in the treatment of certain patients (e.g., those with bronchospastic airway or COPD). Of the -blockers listed, acebutolol is less likely than the rest to block 2-receptors because of its relative cardioselectiveblocking activity. Acebutolol also has a long duration of action, which could be helpful in the noncompliant patient by requiring fewer doses per day. Penbutolol has weak intrinsic sympathomimetic activity like pindolol but lacks relative cardioselectivity, despite its long duration of action. Esmolol by nature of its continuous intravenous infusion would not lend itself to chronic ambulatory therapy. Timolol is a long-acting – blocker and lacks the relative cardioselective properties that acebutolol possesses.
IncorrectAnswer & Explanation:
Th e answer is D
Explanation:
Th e -adrenergic blocking agents continue to demonstrate effectiveness in the treatment of hypertension. A major feature of some of these agents is their relative selectivity for 1-receptors (in the heart) rather than for 2-receptors (in the lung), which provides advantages in the treatment of certain patients (e.g., those with bronchospastic airway or COPD). Of the -blockers listed, acebutolol is less likely than the rest to block 2-receptors because of its relative cardioselectiveblocking activity. Acebutolol also has a long duration of action, which could be helpful in the noncompliant patient by requiring fewer doses per day. Penbutolol has weak intrinsic sympathomimetic activity like pindolol but lacks relative cardioselectivity, despite its long duration of action. Esmolol by nature of its continuous intravenous infusion would not lend itself to chronic ambulatory therapy. Timolol is a long-acting – blocker and lacks the relative cardioselective properties that acebutolol possesses.